

NIH/NIAID Radiation/Nuclear Medical Countermeasures Development Program

Bert W. Maidment, Ph.D.

Associate Director for Product Development

Division of Allergy, Immunology, and Transplantation

National Institute of Allergy and Infectious Diseases

National Institutes of Health

June 15, 2011



Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE JUN 2011		2. REPORT TYPE		3. DATES COVERED 00-00-2011 to 00-00-2011	
4. TITLE AND SUBTITLE NIH/NIAID Radiation/Nuclear Medical Countermeasures Development Program				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) National Institute of Allergy and Infectious Diseases, Division of Allergy, Immunology, and Transplantation, 6610 Rockledge Drive, Room 5321, Bethesda, MD, 20892-6612				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES Presented during the Radiation Countermeasures Symposium, June 15, 2011 Armed Forces Radiobiology Research Institute at the Uniformed Services University in Bethesda, Maryland					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Same as Report (SAR)	18. NUMBER OF PAGES 20	19a. NAME OF RESPONSIBLE PERSON
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			

NIAID Radiation/Nuclear Medical Countermeasures Development Program

- **HHS assigned NIH/NIAID with the responsibility to identify, characterize and develop new medical countermeasure products against radiological and nuclear attacks that may cause a public health emergency.**
- **Research priority areas of the program are to develop:**
 - **Drugs to treat or mitigate radiation injury**
 - **Drugs to remove radioactive materials from the body**
 - **Biodosimetry tools to determine levels of radiation exposure received by an individual**

Types of Radiation Exposure

- Radiological terrorist events
 - RDD (Dirty Bombs)
 - RED
 - Food or Water Contamination
- Nuclear detonation
- Accident
 - Power Plant Release
 - Sealed radiological sources



NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Chemical Threats



05.2005

NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Radiological and Nuclear Threats



Department of Health and Human Services
National Institutes of Health
National Institute of Allergy and Infectious Diseases
NIH Publication No. 05-5606



Components of NIH Strategic Plan and Research Agenda

- **Basic & Translational Research**
- **Radiation Biodosimetry**
- **Focused Product Development**
- **Infrastructure for Research & Product Development**



Radiation Countermeasure Mission Space

■ ARS/DEARE

- Hematopoietic ARS:
 - Neutropenia
 - Thrombocytopenia
 - Anemia
 - Lymphopenia
- GI ARS
- CNS Injury
- Cutaneous Injury
- Lung Injury
- Kidney Injury
- Combined Radiation Injury

■ Biodosimetry Methods and Devices

■ Radionuclide Threats

- Am-241
- Co-60
- Cs-137
- I-131
- Ir-192
- Po-210
- Pu-238/239
- Sr-90
- U-235

■ Late Effects

- Carcinogenesis
- Cardiovascular Disease
- Cataractogenesis

Radiation/Nuclear Medical Countermeasures

■ Mechanisms of Action

- Anti-oxidants**
- Anti-inflammatories**
- Anti-apoptotics**
- Growth factors and cytokines**
- Cell-based therapies**
- Others**

■ Radiation Syndromes

- Acute radiation syndromes (HE, GI, CNS)**
- Delayed effects of radiation exposure (skin, lung, kidney, others)**

■ Radionuclides

- Blocking agents**
- Decorporation agents**


NIAID's Radiation/Nuclear Medical Countermeasures Program



Build Infrastructure
and Research Capacity



Basic Research and
Discovery



ARS Treatments and
Radionuclide Decorporation
Agents Development



Biodosimetry

NIAID

Product
Development
Support Services



Radiation/Nuclear Medical Countermeasure Development Programs

■ Cooperative Agreements

- Centers for Medical Countermeasures against Radiation

■ Specific Tissue Injury Grants

- Immune reconstitution
- Oral Decorporation Agents
- Mechanisms, Diagnostics, and Medical Countermeasures (MCMs)
- Gastrointestinal MCMs
- Lung MCMs
- Skin MCMs
- Combined Injury MCMs

■ SBIR

- Medical Countermeasure Development
- NIAID Omnibus

■ Contracts

- Oral Forms of DTPA (2)
- RERF
- Product Development Support Services

■ Inter/intra Agency Agreements


- NCI
- NIA
- NIDDK
- NIH RAID
- AFRRRI

■ Company Collaborations

- Contacts and presentations
- Candidate efficacy screen
- Candidate Optimization
- Candidate Development

■ International Collaborations

Centers for Medical Countermeasures against Radiation – 2010-2014




MCM Tissue Specific Injury Mitigation Grant Programs:

- **Investigator-initiated awards (R01s); 11 grants**
- **Radiation Combined Injury (R21/R33s); 11 grants**
- **Thrombocytopenia; 7 grants**
- **Lung Radiation Injury; 9 grants**
- **Cutaneous Radiation Injury; 4 grants**
- **RC2 GO Grants; 5 GI and 1 Decorporation Agent**

Product Development Support Services Contractor Capabilities

- Evaluate efficacy of candidate countermeasures
 - Acute Radiation Syndrome
 - Rodent hematological and gastrointestinal models
 - NHP hematological models
 - Developing canine hematological model (Thrombocytopenia)
 - Developing NHP gastrointestinal model
 - Radionuclide Decorporation Agents
- cGMP manufacturing support and stability studies
- GLP toxicology and safety pharmacology studies
- GLP pivotal animal efficacy studies (Animal Rule)
 - NHP and rodent models for efficacy in ARS
- Phase I clinical safety and pharmacokinetic studies
- FDA submission support for p-IND

Radiation/Nuclear Medical Countermeasure Product Development Pathway



Radionuclide Medical Countermeasures Development Programs

■ Background

- Oral administration for mass casualty use**
- Enhanced decorporation efficacy**
- Increase range of radionuclides**

■ Contract and Grant Programs

- Oral Form of Diethylenetriaminepentaacetate (DTPA)**
- Oral Radionuclide Decorporation Agents**

Biodosimetry Program


■ Technical Requirements of a Biodosimetry Architecture

- Capability for rapid screening of large populations
- Sufficiently accurate to guide clinical decision-making
- Sufficiently flexible to address different needs for different types of radiation exposures

■ Medical / Operational Impact

- Identification of patients requiring urgent medical assessment/triage
- Optimization of resource allocation
- Reassurance for anxious individuals
- Improved risk assessment for delayed or late effects of radiation exposure
- Identify specific tissue/organ injuries
- Monitoring of therapy (bioassays)

Biodosimetry Architecture



Successful Radiation/Nuclear Medical Countermeasure Product Development

- **Urgency and priority for national preparedness for rapid development and licensure of safe and effective medical countermeasures**
- **Success will require unprecedented collegial collaboration, communication, coordination, and interaction among**
 - **Government agencies especially FDA, CDC, NIH, HHS, DOD**
 - **Pharmaceutical industry**
 - **Academia**
- **Product development plans need to be developed with label indication in mind**

Bridging the Radiation/Nuclear Medical Countermeasure “Animal Rule Pathway”

Discovery, Research,
and, Development



Licensure and
Procurement

Government, Academia, Corporate Partnerships

Food and Drug Administration – CDER, CBER, and CDRH

National Institute of Allergy and Infectious Diseases

HHS/Biomedical Advanced Research and Development Authority

NIAID Radiation/Nuclear Medical Countermeasures Development Program Team

- **Bert Maidment, Ph.D., Associate Director for Product Development**
- **Narayani Ramakrishnan, Ph.D., Program Officer**
- **Andrea DiCarlo, Ph.D., Program Officer**
- **David Cassatt, Ph.D., Program Officer**
- **Mai-Kim Norman, Health Specialist**
- **Francesca Macchiarini, Program Officer**
- **Erika Davies, Ph.D., AAAS Research Fellow**
- **Christine Czarniecki, Ph.D., Chief, Regulatory Affairs**
- **Jui Shah, Ph.D., Senior Regulatory Affairs Officer**
- **Lawrence Prograis, M.D., Special Programs and Bioethics**

Radiation/Nuclear Medical Countermeasures Product Development Program

- **Bert W. Maidment, PhD**
Associate Director, Product Development
NIAID/DAIT/Office of Product Development
6610 Rockledge Drive, Room 5321
301-594-0641 (Voice)
maidmentb@niaid.nih.gov
- <http://www3.niaid.nih.gov/research/topics/radnuc/>

